Avenue Therapeutics, Inc. Announces Annual Meeting of Stockholders on June 24, 2024

TL;DR

<b>Avenue Therapeutics, Inc. will hold its Annual Meeting of Stockholders virtually on June 24, 2024, to elect directors, ratify auditors, and approve an amendment to its 2015 Incentive Plan.</b>

AI Summary

AVENUE THERAPEUTICS, INC. (ATXI) filed a Proxy Statement (DEF 14A) with the SEC on May 6, 2024. Annual Meeting of Stockholders to be held virtually on June 24, 2024, at 9:30 a.m. ET. Stockholders will vote on the election of six directors for a one-year term. KPMG LLP to be ratified as independent registered public accounting firm for the year ending December 31, 2024. Proposal to amend the 2015 Incentive Plan to increase authorized shares by 5,000,000. The amendment to the 2015 Plan aims to extend its term to June 24, 2034, and increase share limits for options and non-employee directors.

Why It Matters

For investors and stakeholders tracking AVENUE THERAPEUTICS, INC., this filing contains several important signals. The proposed amendment to the 2015 Incentive Plan could significantly increase the number of shares available for equity compensation, potentially diluting existing shareholders if not managed carefully. The ratification of KPMG LLP as the independent auditor is a standard procedural step, but any concerns raised during their audit could impact investor confidence.

Risk Assessment

Risk Level: low — AVENUE THERAPEUTICS, INC. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting with standard proposals, posing no immediate significant risk.

Analyst Insight

Stockholders should carefully review the details of the proposed amendment to the 2015 Incentive Plan, particularly the increase in authorized shares and its potential impact on dilution, before voting.

Key Numbers

• June 24, 2024 — Annual Meeting Date (Date of the Annual Meeting of Stockholders.)
• 9:30 a.m. Eastern Time — Annual Meeting Time (Time of the Annual Meeting of Stockholders.)
• six — Directors to be Elected (Number of directors to be elected at the Annual Meeting.)
• December 31, 2024 — Fiscal Year End (Fiscal year for which KPMG LLP is proposed to be ratified as auditor.)
• 5,000,000 shares — Share Increase (Number of shares to be added to the 2015 Incentive Plan.)
• June 24, 2034 — Plan Extension Date (Extended term date for the 2015 Incentive Plan.)
• 500,000 — Annual Share Limit for Directors (Increased annual share limit for awards to non-employee directors.)

Key Players & Entities

• Avenue Therapeutics, Inc. (company) — Registrant and filer of the proxy statement.
• KPMG LLP (company) — Proposed independent registered public accounting firm.
• June 24, 2024 (date) — Date of the Annual Meeting of Stockholders.
• 2015 Incentive Plan (plan) — Plan to be amended regarding share authorization.
• 5,000,000 shares (dollar_amount) — Increase in authorized shares under the 2015 Incentive Plan.

FAQ

Risk Factors

• Compliance with SEC Regulations [low — regulatory]: The company must comply with all SEC regulations regarding proxy solicitations and annual meetings, including timely filing and accurate disclosure.
• Shareholder Approval for Incentive Plan [low — financial]: The effectiveness of the proposed increase in authorized shares under the 2015 Incentive Plan is contingent upon shareholder approval.

Key Dates

• 2024-06-24: Annual Meeting of Stockholders — Key date for voting on director elections, auditor ratification, and incentive plan amendments.

Glossary

DEF 14A

Definitive Proxy Statement filed with the SEC. (This filing provides detailed information about the matters to be voted on at the annual meeting.)

Filing Documents

• atxi20240319_def14a.htm (DEF 14A) — 506KB
• at.jpg (GRAPHIC) — 9KB
• proxyback.jpg (GRAPHIC) — 59KB
• proxyfront.jpg (GRAPHIC) — 66KB
• pvptsr.jpg (GRAPHIC) — 31KB
• 0001437749-24-014691.txt (&nbsp;) — 719KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 17 Summary Compensation Table 17 Narrative to Summary Compensation Table 18 i Table of Contents Equity Awards 18 Outstanding Equity Awards at 2023 Fiscal Year End 19 401(k) Plan 19 Clawback Policy 19 DIRECTOR COMPENSATION 20 Director Compensation Program 20 Director Compensation Table 20 PAY VERSUS PERFORMANCE DISCLOSURE 21 Analysis of the Information Presented in the Pay Versus Performance Table 22 RELATED-PERSON TRANSACTIONS 23 STOCK OWNERSHIP OF OUR DIRECTORS, EXECUTIVE OFFICERS, AND 5% BENEFICIAL OWNERS 26 EQUITY COMPENSATION PLAN INFORMATION 27 PROPOSAL NO. 1 ELECTION OF DIRECTORS; NOMINEES 28 PROPOSAL NO. 2 RATIFICATION OF APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 29 PROPOSAL NO. 3 APPROVAL OF AN AMENDMENT TO OUR 2015 INCENTIVE PLAN 30 ADDITIONAL INFORMATION 36 Householding of Annual Meeting Materials 36 Stockholder Proposals for Our 2025 Annual Meeting 36 Other Matters 36 Solicitation of Proxies 36 Incorporation of Information by Reference 37 ii Table of Contents QUESTIONS AND ANSWERS Q: What is the purpose of the Annual Meeting? A. At the Annual Meeting, our stockholders will act upon the matters outlined in the Notice of Annual Meeting of Stockholders accompanying this proxy statement, including (i) the election of six directors for a term of one year until our 2025 Annual Meeting of Stockholders or until their successors are duly elected and qualified in accordance with our Second Amended and Restated Bylaws ("Bylaws"), (ii) ratifying the appointment of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2024, (iii) approving an amendment to the 2015 Plan to increase the number of authorized shares issuable thereunder by 5,000,000 shares, which will extend the term of the 2015 Plan to June 24, 2034, increase the limit of shares that may be issued upon the exe

View Full Filing

View this DEF 14A filing on SEC EDGAR